Home >>
Article >>
Named Patient Program in India: Myths vs. Facts
Named Patient Program in India: Myths vs. Facts
Understanding Named Patient Programs in India: Myths and Realities
When a patient faces a serious or life-threatening condition and needs a medicine that isn't yet approved or available in India, a Named Patient Program (NPP) can be a compliant way to access the unapproved medicine. Yet this pathway is widely misunderstood — some assume it's illegal, impossibly slow, or a way to buy any drug on demand. This post extracts the myths from the facts about Named Patient Programs in India.
What Is a Named Patient Program in India?
A Named Patient Program (NPP) is a regulated pathway that allows a patient to access a medicine that is approved or available in the global market but not yet approved or marketed in India, on the prescription of their treating physician. India regulates access to unapproved or unavailable medicines through the Central Drugs Standard Control Organization (CDSCO) under the Drugs and Cosmetics Act, 1940.
It is similar to the Compassionate Use Program (CUP), but not exactly the same. A Named Patient Program allows access to drugs approved in the global market but not in India, while Compassionate Use provides access to investigational treatments; both require CDSCO approvals but differ in the drug's regulatory status.
Myths vs. Facts About Named Patient Programs in India:
Myth 1: Named Patient Programs are illegal in India.
Fact: They are legal and regulated. Access to unapproved medicines for individual patients is permitted under CDSCO oversight, within the framework of the Drugs and Cosmetics Act, 1940. This is a recognised regulatory route, not a grey-market workaround.
Myth 2: Anyone can buy unapproved medicines through an NPP.
Fact: No. Access requires a licensed physician's prescription and is intended for patients with serious or life-threatening conditions, or unmet medical needs, who have limited or no approved alternative treatments. The process is initiated by the patient's treating physician, who requests access for a patient with a serious or life-threatening condition who has exhausted other treatment options. These medicines are never sold over the counter.
Myth 3: A Named Patient Program and Compassionate Use are exactly the same.
Fact: They overlap but are different. An NPP typically refers to a medicine already approved by regulators in the global market but not yet available in India. Compassionate use, under India's framework, allows import of an unapproved new drug that is undergoing a Phase 3 clinical trial — in India or abroad — for those with life-threatening disease, serious permanent disability, or an unmet medical need. The drug's approval status is the key distinction.
Myth 4: NPPs are only for patients enrolled in clinical trials.
Fact: An NPP is specifically for patients outside of clinical trials. It exists so that patients who cannot join a trial, and cannot wait for full Indian approval, may still access a required therapy under medical supervision.
Myth 5: The process takes years and is impossibly bureaucratic.
Fact: Timelines are defined. CDSCO reviews compassionate-use and named-patient-type applications and supporting documentation within about 10-15 days. While documentation must be complete and accurate, the process is structured and predictable rather than open-ended.
Myth 6: Patients can import any quantity of any drug for personal use.
Fact: Personal import is limited to small quantities intended for the named patient’s own treatment. It must be supported by a valid prescription and the required documentation. Larger or commercial quantities require separate import registration and licensing. They cannot be obtained through the individual-patient route.
Myth 7: NPP medicines are untested or unsafe "experimental dumping."
Fact: Medicines accessed through an NPP are typically already approved by stringent international regulators such as the US FDA or EMA, or are in advanced clinical development. Quality sourcing, proper storage, documentation, and pharmacovigilance still apply throughout the supply chain.
Myth 8: An NPP means the medicine is free or automatically reimbursed. "
Fact: An NPP is an access pathway, not a funding mechanism. The cost of the medicine, and any insurance or reimbursement, is a separate matter to be arranged by the patient, hospital, or payer.
How the Named Patient Program Process Works (In Brief):
- A physician identifies that a patient needs a medicine unavailable or unapproved in India.
- The physician (or hospital) prepares the clinical justification and required documentation.
- An application is made to CDSCO, with ethics committee and informed-consent requirements as applicable.
- Once approval is granted, the medicine is sourced from leading global manufacturers or approved stockists and imported with proper customs and regulatory documentation.
- The patient receives the medicine under their physician's supervision, with appropriate monitoring.
How Ikris Pharma Network Supports Named Patient Programs?
Navigating an NPP can feel overwhelming for patients and busy clinicians. Ikris Pharma Network (IPN) supports physicians, hospitals, and patients by sourcing medicines from leading manufacturers and approved stockists. The company also helps with regulatory documentation, CDSCO coordination, and customs-related processes required for compliant medicine access.
In addition, IPN provides GDP-aligned international logistics support, including temperature-controlled and cold-chain handling where required. The goal is to make a complex, time-sensitive process clearer and more manageable, always within the bounds of Indian regulations.
Frequently Asked Questions (FAQs):
Is a Named Patient Program legal in India?
Yes. Named Patient Programs are legal under CDSCO regulations. Patients can access unapproved or unavailable medicines when prescribed by a physician for serious or life-threatening conditions, subject to regulatory approval.
What is the difference between a Named Patient Program and Compassionate Use in India?
A Named Patient Program generally provides access to medicines approved abroad but not in India, while Compassionate Use covers investigational drugs still undergoing Phase 3 trials. Both require CDSCO involvement.
who can apply for a named patient program in india?
The process is initiated by a treating physician or hospital, not the patient directly. Sourcing partners can assist with documentation and logistics.
Can a patient import an unapproved medicine into India for personal use?
In limited cases, yes. Small quantities may be imported for a named patient's own treatment with a valid prescription and the required documentation. Commercial or bulk quantities require separate import registration and licensing.
How much does a Named Patient Program cost, and does insurance cover it?
A Named Patient Program is an access pathway, not a funding mechanism. The cost depends on the medicine, quantity, and sourcing, and is borne by the patient, hospital, or payer. Insurance coverage varies by policy, so confirm it with your insurer in advance.
Are medicines accessed through a Named Patient Program safe?
Generally, yes. These medicines are usually already approved by stringent regulators such as the US FDA or EMA, or are in advanced clinical development. They must be sourced from legitimate channels, stored and transported correctly, and used under a physician's supervision.
What documents are required for a Named Patient Program in India?
Prescription (signed and stamped) from a treating Doctor - along with the doctor’s registration number; scanned copies of the patient’s medical records or case history papers; and a valid photo ID such as a Passport, Aadhaar Card, or any government-issued ID. We will mail an Order Form, which must be filled out, signed, and submitted along with the required documents.
Key Takeaways:
- Named Patient Programs in India are a legal, CDSCO-regulated route to access unapproved or unavailable medicines.
- They require a physician's prescription and are meant for serious, life-threatening, or unmet medical conditions.
- NPP (drugs approved in the global market) and Compassionate Use (investigational drugs in trials) are related but distinct.
- The pathway is physician-initiated and limited to appropriate quantities.
Medical & Legal Disclaimer:
This article is for general informational purposes only. Do not consider it as medical or legal advice. Indian regulations govern access to unapproved medicines and require the involvement of a licensed physician and the relevant regulatory authorities. Always consult your treating doctor and verify current CDSCO requirements before pursuing any access pathway.
References: